DEEAH syndrome (developmental delay with endocrine, exocrine, autonomic, and hematologic abnormalities) is a rare autosomal recessive multisystem disorder caused by biallelic loss-of-function variants in MADD (MAP-kinase-activating death domain protein; hgnc:6766 - the gene, not to be confused with the unrelated metabolic disorder abbreviated MADD, multiple acyl-CoA dehydrogenase deficiency). MADD is a large multidomain protein that acts as a DENN-domain guanine-nucleotide exchange factor (GEF) for Rab3 and Rab27 small GTPases, regulates vesicular trafficking, and transduces TNF-alpha/neurotrophin-receptor survival signaling that restrains apoptosis. Biallelic MADD loss produces an allelic phenotypic spectrum. This entry curates that biallelic-MADD spectrum as a single disease with a conserved gene-and-mechanism pathograph rather than splitting it into subtypes: its severe end is DEEAH proper ("Group 1", OMIM #619004), with profound developmental delay and combined endocrine, exocrine, sensory/autonomic, and hematologic dysfunction and a potentially fatal course in the first years of life; the milder, predominantly neurological allelic form ("Group 2", the neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, OMIM #619005) shares developmental delay, hypotonia, speech impairment, and seizures with better survival. Phenotype frequencies below are reported for the severe end unless noted; features drawn from the milder form (e.g. seizures) are labeled as spectrum features.
Ask a research question about Deeah Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Deeah Syndrome
creation_date: "2026-09-05T00:00:00Z"
category: Mendelian
description: >-
DEEAH syndrome (developmental delay with endocrine, exocrine, autonomic, and
hematologic abnormalities) is a rare autosomal recessive multisystem disorder
caused by biallelic loss-of-function variants in MADD (MAP-kinase-activating
death domain protein; hgnc:6766 - the gene, not to be confused with the
unrelated metabolic disorder abbreviated MADD, multiple acyl-CoA dehydrogenase
deficiency). MADD is a large multidomain protein that acts as a DENN-domain
guanine-nucleotide exchange factor (GEF) for Rab3 and Rab27 small GTPases,
regulates vesicular trafficking, and transduces TNF-alpha/neurotrophin-receptor
survival signaling that restrains apoptosis. Biallelic MADD loss produces an
allelic phenotypic spectrum. This entry curates that biallelic-MADD spectrum
as a single disease with a conserved gene-and-mechanism pathograph rather than
splitting it into subtypes: its severe end is DEEAH proper ("Group 1", OMIM
#619004), with profound developmental delay and combined endocrine, exocrine,
sensory/autonomic, and hematologic dysfunction and a potentially fatal course
in the first years of life; the milder, predominantly neurological allelic form
("Group 2", the neurodevelopmental disorder with dysmorphic facies and thin
corpus callosum, OMIM #619005) shares developmental delay, hypotonia, speech
impairment, and seizures with better survival. Phenotype frequencies below are
reported for the severe end unless noted; features drawn from the milder form
(e.g. seizures) are labeled as spectrum features.
disease_term:
preferred_term: DEEAH syndrome
term:
id: MONDO:0033561
label: deeah syndrome
parents:
- Autosomal recessive neurodevelopmental disorder
- Rab GTPase / vesicular trafficking disorder
external_assertions:
- name: OMIM DEEAH syndrome record
source: OMIM
assertion_type: disease_record
external_id: OMIM:619004
description: >-
OMIM entry #619004 for DEEAH syndrome (developmental delay with endocrine,
exocrine, autonomic, and hematologic abnormalities), the severe biallelic-MADD
phenotype. The milder allelic neurodevelopmental disorder is OMIM #619005.
- name: Orphanet DEEAH syndrome record
source: Orphanet
assertion_type: disease_record
external_id: ORPHA:686495
description: Orphanet disorder record for DEEAH syndrome.
- name: MedGen concept
source: MedGen
assertion_type: disease_record
external_id: MedGen:C5436579
description: NCBI MedGen concept C5436579 cross-referenced by MONDO:0033561.
inheritance:
- name: Autosomal recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
description: >-
DEEAH syndrome is inherited in an autosomal recessive pattern; affected
individuals carry biallelic (homozygous or compound heterozygous)
loss-of-function MADD variants, with unaffected heterozygous carrier
parents. Many reported families are consanguineous.
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a pleiotropic disorder with a unique constellation of neurological, endocrine, exocrine, and haematological findings that is caused by biallelic MADD variants"
explanation: Establishes biallelic (recessive) MADD variants as the cause.
genetic:
- name: MADD biallelic loss-of-function
association: Causative
gene_term:
preferred_term: MADD
term:
id: hgnc:6766
label: MADD
notes: >-
Biallelic (homozygous or compound heterozygous) germline MADD variants -
including nonsense, frameshift, splice-site, and missense alleles - cause the
disorder. Patient fibroblasts show aberrant MADD transcripts and drastic
reduction or loss of MADD protein, consistent with a loss-of-function
mechanism. MADD encodes the MAP-kinase-activating death domain protein (also
called DENN/MADD, IG20, Rab3-GEP), a DENN-domain guanine-nucleotide exchange
factor for Rab3 and Rab27. This is the gene MADD, distinct from the metabolic
disorder abbreviation MADD (multiple acyl-CoA dehydrogenase deficiency).
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we collected 23 patients with 21 different pathogenic MADD variants identified by next-generation sequencing"
explanation: Establishes MADD as the causative gene with a spectrum of pathogenic variants.
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Relative quantification of MADD mRNA and protein in fibroblasts of five affected individuals showed a drastic reduction or loss of MADD"
explanation: Documents loss of MADD protein in patient cells, supporting a loss-of-function mechanism.
pathophysiology:
- name: Biallelic MADD Loss of Function
description: >-
Biallelic pathogenic MADD variants generate aberrant transcripts and cause a
drastic reduction or loss of MADD protein, removing a multifunctional
signaling and trafficking regulator from cells throughout the body.
biological_scale: MOLECULAR
genes:
- preferred_term: MADD
term:
id: hgnc:6766
label: MADD
genetic_context:
variant_origin: GERMLINE
functional_impact_category: LOSS_OF_FUNCTION
description: >-
Biallelic (homozygous or compound heterozygous) germline MADD variants,
including nonsense, frameshift, splice-site, and missense alleles, with
loss of MADD protein in patient cells.
downstream:
- target: Impaired Rab-GEF Vesicular Trafficking
causal_link_type: DIRECT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "MADD deficiency underlies multiple cellular defects that can be attributed to alterations of TNF-α-dependent signalling pathways and defects in vesicular trafficking"
explanation: A conclusion from the patient-fibroblast functional studies linking MADD loss to defective vesicular trafficking.
- target: Impaired TNF-alpha Cytoprotective Signaling
causal_link_type: DIRECT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Treatment of patient-derived fibroblasts with TNF-α resulted in reduced phosphorylation of the extracellular signal-regulated kinases 1 and 2"
explanation: Shows MADD loss disrupts TNF-alpha-driven ERK survival signaling.
molecular_functions:
- preferred_term: MADD guanyl-nucleotide exchange factor activity toward Rab GTPases
term:
id: GO:0005085
label: guanyl-nucleotide exchange factor activity
modifier: LOSS_OF_FUNCTION
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Analysis of mRNA revealed multiple aberrant MADD transcripts in two patient-derived fibroblast cell lines"
explanation: Documents the aberrant transcripts underlying loss of MADD protein.
- name: Impaired Rab-GEF Vesicular Trafficking
description: >-
MADD is a DENN-domain guanine-nucleotide exchange factor that activates Rab3
and Rab27 (and additional Rab substrates such as Rab8B, Rab15, Rab26,
Rab37). Loss of MADD impairs Rab-dependent membrane trafficking and
regulated secretion/endocytosis; patient cells show a defect in endocytosis
of epidermal growth factor. Because Rab3/Rab27-dependent regulated exocytosis
underlies neurotransmitter, hormone, and other secretory-granule release,
this trafficking defect propagates to secretory tissues. Different missense
alleles impair Rab activation to different degrees, offering a mechanistic
basis for the severity spectrum (see the P372L/L346P evidence below).
biological_scale: CELLULAR
downstream:
- target: Endocrine and Exocrine Secretory Dysfunction
causal_link_type: DIRECT
- target: Autonomic and Sensory Nervous System Dysfunction
causal_link_type: DIRECT
biological_processes:
- preferred_term: Rab-regulated vesicle-mediated transport
term:
id: GO:0016192
label: vesicle-mediated transport
modifier: DECREASED
- preferred_term: regulated exocytosis of secretory granules
term:
id: GO:0045055
label: regulated exocytosis
modifier: DECREASED
- preferred_term: receptor internalization (EGF endocytosis)
term:
id: GO:0031623
label: receptor internalization
modifier: DECREASED
evidence:
- reference: PMID:40812422
reference_title: "Neurodevelopmental disorder mutations in the exchange factor DENN/MADD disrupt activation of Rab GTPases."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "DENN domain-bearing proteins have guanine nucleotide exchange factor activity toward Rab GTPases"
explanation: Establishes MADD's DENN domain as a Rab-GEF, the activity lost in disease.
- reference: PMID:40812422
reference_title: "Neurodevelopmental disorder mutations in the exchange factor DENN/MADD disrupt activation of Rab GTPases."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We confirmed known interactions of DENN/MADD with Rab3A, Rab3B, Rab3C, Rab3D, and Rab27B and identified four new potential substrates, Rab8B, Rab15, Rab26, and Rab37"
explanation: Identifies the Rab GTPase substrates whose activation depends on MADD.
- reference: PMID:40812422
reference_title: "Neurodevelopmental disorder mutations in the exchange factor DENN/MADD disrupt activation of Rab GTPases."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Loss of the catalytic activity because of the P372L mutation abolished the mitochondrial recruitment of all Rabs, whereas the L346P mutation abolished the recruitment for all Rabs except Rab3C and Rab27B, which is further explained through structural biology."
explanation: Substrate-selective loss of Rab activation (all Rabs vs all-but-Rab3C/Rab27B) provides a mechanistic basis for the severe-versus-milder split.
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We analysed internalization of epidermal growth factor in patient cells and identified a defect in endocytosis of epidermal growth factor"
explanation: Demonstrates a vesicular-trafficking (endocytosis) defect in patient cells.
- name: Impaired TNF-alpha Cytoprotective Signaling
description: >-
MADD couples TNF-receptor and neurotrophin-receptor engagement to
pro-survival ERK1/2 (MAPK) activation, restraining apoptosis. Loss of MADD
reduces TNF-alpha-induced ERK1/2 phosphorylation, shifting the balance toward
programmed cell death.
biological_scale: MOLECULAR
downstream:
- target: Increased Apoptosis
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
directness: INDIRECT
evidence_source: IN_VITRO
snippet: "enhanced activation of the pro-apoptotic enzymes caspase-3 and -7 and increased apoptosis compared to control cells"
explanation: Increased caspase-3/-7 activation and apoptosis was measured in patient fibroblasts; its extension to neurons in vivo is an inference.
biological_processes:
- preferred_term: tumor necrosis factor-mediated signaling pathway
term:
id: GO:0033209
label: tumor necrosis factor-mediated signaling pathway
modifier: DECREASED
- preferred_term: ERK1 and ERK2 survival cascade
term:
id: GO:0070371
label: ERK1 and ERK2 cascade
modifier: DECREASED
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Treatment of patient-derived fibroblasts with TNF-α resulted in reduced phosphorylation of the extracellular signal-regulated kinases 1 and 2"
explanation: Directly measures reduced ERK1/2 activation in patient cells.
- name: Increased Apoptosis
description: >-
Failure of MADD-dependent survival signaling activates the effector caspases
caspase-3 and caspase-7, increasing apoptosis. This was demonstrated in
patient-derived fibroblasts; loss of this anti-apoptotic brake in neurons and
other post-mitotic and secretory cells is the inferred in-vivo driver of the
developmental and multisystem phenotype.
biological_scale: CELLULAR
downstream:
- target: Global developmental delay
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Autonomic and Sensory Nervous System Dysfunction
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
cell_types:
- preferred_term: fibroblast (patient-derived; neuronal extrapolation inferred)
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: apoptotic process
term:
id: GO:0006915
label: apoptotic process
modifier: INCREASED
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "enhanced activation of the pro-apoptotic enzymes caspase-3 and -7 and increased apoptosis compared to control cells"
explanation: Documents increased effector-caspase activation and apoptosis in patient fibroblasts on loss of MADD.
- name: Endocrine and Exocrine Secretory Dysfunction
description: >-
Because Rab3/Rab27-dependent regulated secretion underlies hormone and
exocrine-gland output, MADD deficiency produces combined endocrine and
exocrine dysfunction. Reported manifestations include dysregulated glucose
homeostasis (neonatal hypoglycemia and hyperglycemia), hypopituitarism with
growth hormone deficiency, and other endo- and exocrine gland involvement.
MADD-deficient stem-cell-derived pancreatic islets show reduced beta-cell
number, decreased insulin content, and an increased proinsulin-to-insulin
ratio.
biological_scale: ORGANISM
downstream:
- target: Hypoglycemia
causal_link_type: DIRECT
- target: Hypopituitarism
causal_link_type: DIRECT
- target: Secondary growth hormone deficiency
causal_link_type: DIRECT
biological_processes:
- preferred_term: regulated exocytosis (hormone/secretory release)
term:
id: GO:0045055
label: regulated exocytosis
modifier: DECREASED
cell_types:
- preferred_term: secretory cell
term:
id: CL:0000151
label: secretory cell
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "severe developmental delay, endo- and exocrine dysfunction, impairment of the sensory and autonomic nervous system, and haematological anomalies"
explanation: Establishes combined endocrine and exocrine dysfunction as a core DEEAH feature.
- reference: PMID:38775154
reference_title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We observed reduced numbers of β cells, decreased insulin content, and increased proinsulin-to-insulin ratio in dex30 human embryonic stem cell-derived pancreatic islets."
explanation: Anchors the endocrine (islet) dysfunction in a MADD-deficient stem-cell-derived islet model.
- name: Autonomic and Sensory Nervous System Dysfunction
description: >-
MADD deficiency impairs the physiological function of the sensory and
autonomic nervous system, part of the pleiotropic DEEAH phenotype and a
contributor to feeding, gastrointestinal, dysautonomic, and central
respiratory (apnea) problems.
biological_scale: ORGANISM
downstream:
- target: Recurrent apnea
causal_link_type: DIRECT
- target: Pain insensitivity
causal_link_type: DIRECT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "reveal its physiological role in regulating the function of the sensory and autonomic nervous system and endo- and exocrine glands"
explanation: Concluding statement of the functional study attributing sensory/autonomic regulation to MADD.
phenotypes:
- name: Global developmental delay
description: >-
Profound-to-severe global developmental delay is a defining feature; the
severe (DEEAH/Group 1) form shows profound delay.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
frequency: VERY_FREQUENT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Group 1 consists of 14 patients with severe developmental delay, endo- and exocrine dysfunction, impairment of the sensory and autonomic nervous system, and haematological anomalies"
explanation: Severe developmental delay defines the DEEAH (Group 1) phenotype.
- name: Axial hypotonia
description: Neonatal/axial hypotonia is present in essentially all reported patients.
phenotype_term:
preferred_term: Axial hypotonia
term:
id: HP:0008936
label: Axial hypotonia
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "severe neonatal hypotonia, failure to thrive, multiple organ dysfunction, and early lethality"
explanation: Neonatal hypotonia is a consistent feature at the severe end of the spectrum.
- name: Seizures
description: >-
Seizures (often generalized tonic-clonic, sometimes fever- or
hypoglycemia-triggered) occur across the spectrum and are a defining feature
of the milder (Group 2) allelic form.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
frequency: FREQUENT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "mild-to-severe developmental delay, hypotonia, speech impairment, and seizures"
explanation: Seizures are part of the MADD-related neurodevelopmental phenotype (Group 2 description).
- name: Failure to thrive
description: Failure to thrive and poor growth are characteristic of the severe form.
phenotype_term:
preferred_term: Failure to thrive
term:
id: HP:0001508
label: Failure to thrive
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "failure to thrive (>70% of cases), hematological abnormalities (>90% of cases), and neonatal hypoglycemia (>90% of cases) are consistent features in the lethal group"
explanation: Failure to thrive is a consistent (>70%) severe-end feature.
- name: Chronic diarrhea
description: >-
Chronic diarrhea (with recurrent infections) reflects exocrine and
autonomic gastrointestinal involvement.
phenotype_term:
preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "displaying neonatal respiratory distress, hypotonia and chronic diarrhea"
explanation: Chronic diarrhea is reported at the severe end of the spectrum.
- name: Anemia
category: Hematologic
description: >-
Anemia is the most consistent hematologic anomaly, sometimes requiring
transfusion; thrombocytopenia or thrombocytosis also occur.
phenotype_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "hematological abnormalities (>90% of cases), and neonatal hypoglycemia (>90% of cases) are consistent features in the lethal group"
explanation: Hematological abnormalities (chiefly anemia) are present in >90% of severe-form patients.
- name: Thrombocytopenia
category: Hematologic
description: >-
Thrombocytopenia (with anemia and a prolonged bleeding profile) is among the
reported hematologic anomalies, reported in roughly 35-40% of cohort
patients, sometimes requiring transfusion.
phenotype_term:
preferred_term: Thrombocytopenia
term:
id: HP:0001873
label: Thrombocytopenia
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The only notable abnormal laboratory findings were severe microcytic anemia, thrombocytopenia, and prolonged bleeding profile that nictitated blood transfusion."
explanation: Explicitly reports thrombocytopenia (with anemia) among the hematologic findings.
- name: Hypoglycemia
category: Endocrine
description: >-
Dysregulated glucose homeostasis, including neonatal hypoglycemia (and in
some patients hyperglycemia), reflects endocrine dysfunction.
phenotype_term:
preferred_term: Hypoglycemia
term:
id: HP:0001943
label: Hypoglycemia
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "failure to thrive (>70% of cases), hematological abnormalities (>90% of cases), and neonatal hypoglycemia (>90% of cases) are consistent features in the lethal group"
explanation: Neonatal hypoglycemia is a consistent (>90%) endocrine feature of the severe form.
- name: Hypopituitarism
category: Endocrine
description: >-
Hypopituitarism is a common endocrine manifestation, most often with neonatal
growth hormone deficiency and low FSH.
phenotype_term:
preferred_term: Hypopituitarism
term:
id: HP:0040075
label: Hypopituitarism
frequency: FREQUENT
evidence:
- reference: PMID:38775154
reference_title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most of the patients have hypopituitarism, with neonatal growth hormone deficiency (GHD) and low follicle-stimulating hormone (FSH) level being the most common findings"
explanation: States hypopituitarism is present in most patients with biallelic MADD variants.
- name: Secondary growth hormone deficiency
category: Endocrine
description: >-
Neonatal (central/pituitary) growth hormone deficiency is among the most
common endocrine findings, secondary to hypopituitarism.
phenotype_term:
preferred_term: Secondary growth hormone deficiency
term:
id: HP:0008240
label: Secondary growth hormone deficiency
frequency: FREQUENT
evidence:
- reference: PMID:38775154
reference_title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most of the patients have hypopituitarism, with neonatal growth hormone deficiency (GHD) and low follicle-stimulating hormone (FSH) level being the most common findings"
explanation: Neonatal GH deficiency in the setting of hypopituitarism is a secondary (central) GH deficiency.
- name: Abnormal autonomic nervous system physiology
description: >-
Impairment of the autonomic (and sensory) nervous system is a hallmark of
the severe DEEAH phenotype.
phenotype_term:
preferred_term: Abnormal autonomic nervous system physiology
term:
id: HP:0012332
label: Abnormal autonomic nervous system physiology
frequency: VERY_FREQUENT
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "impairment of the sensory and autonomic nervous system"
explanation: Directly supports autonomic nervous system dysfunction.
- name: Pain insensitivity
description: >-
Reduced pain sensation is described in severe (Group 1) patients, interpreted
as a hereditary sensory and autonomic neuropathy type II-like feature of the
sensory axis.
phenotype_term:
preferred_term: Pain insensitivity
term:
id: HP:0007021
label: Pain insensitivity
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the reduced pain sensations among patients of group 1 of Schneeberger and co-authors"
explanation: Reports reduced pain sensation as a Group 1 (severe DEEAH) sensory-axis feature.
- name: Recurrent apnea
description: >-
Recurrent apnea of neonatal onset is reported, consistent with central
autonomic dysregulation of respiration.
phenotype_term:
preferred_term: Recurrent apnea
term:
id: HP:0002104
label: Apnea
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "he was admitted to NICU for 10 days because of cyanosis and the episodes of apnea"
explanation: Documents recurrent apnea in an affected neonate (single-patient report; frequency not established).
- name: Neonatal respiratory distress
description: Neonatal respiratory distress occurs at the severe end of the spectrum.
phenotype_term:
preferred_term: Neonatal respiratory distress
term:
id: HP:0002643
label: Neonatal respiratory distress
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "displaying neonatal respiratory distress, hypotonia and chronic diarrhea"
explanation: Neonatal respiratory distress is reported in severe-form patients.
- name: Congenital heart disease
category: Cardiovascular
description: >-
Congenital heart disease is reported at variable frequency - infrequent
(about 14%) in the original severe cohort but much higher (80-100%) in some
subsequently reported cohorts.
phenotype_term:
preferred_term: Congenital heart disease
term:
id: HP:0001627
label: Abnormal heart morphology
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Interestingly, congenital heart disease was not described as a consistent feature, reported in 2/14 (14%) of cases"
explanation: Reports congenital heart disease at 14% in the original severe cohort.
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "have a much more prevalence of congenital heart disease showing 80% and 100%, respectively."
explanation: Later cohorts report much higher congenital-heart-disease rates (80-100%); pooled across cohorts the feature is frequent.
- name: Arthrogryposis multiplex congenita
description: >-
Distal arthrogryposis (clenched hands, rocker-bottom feet, talipes) has been
reported as an expansion of the MADD phenotype.
phenotype_term:
preferred_term: Arthrogryposis multiplex congenita
term:
id: HP:0002804
label: Arthrogryposis multiplex congenita
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we observed distal arthrogryposis and nonspecific structural brain anomalies in all our patients"
explanation: Arthrogryposis was observed in all patients of this cohort.
- name: Agenesis of corpus callosum
description: >-
Corpus callosum agenesis/hypogenesis and other structural brain anomalies
are reported, including in a severe case with adrenal and scrotal agenesis.
phenotype_term:
preferred_term: Agenesis of corpus callosum
term:
id: HP:0001274
label: Agenesis of corpus callosum
evidence:
- reference: PMID:37932938
reference_title: "Calloso-adreno-scrotal agenesis associated with biallelic MAPK-activating death domain protein (MADD) variant: Further phenotypic delineation of MADD deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The novel findings include corpus callosum agenesis, bilateral adrenal agenesis, scrotal aplasia, and abnormal skin pigmentation"
explanation: Reports corpus callosum agenesis as part of the MADD phenotype (single severe case; frequency not established).
- name: Cryptorchidism
description: >-
Genital anomalies including micropenis and undescended testes are frequently
reported in affected males.
phenotype_term:
preferred_term: Cryptorchidism
term:
id: HP:0000028
label: Cryptorchidism
frequency: FREQUENT
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Genital anomalies (micropenis and undescended testis) have been previously reported in 70% (12/17) of male patients with MADD variants"
explanation: Reports undescended testis (cryptorchidism) in 70% of male patients.
- name: Scrotal aplasia
description: >-
Absence of the scrotum (scrotal aplasia) was a novel finding in a severe case
with corpus callosum and bilateral adrenal agenesis.
phenotype_term:
preferred_term: Scrotal aplasia
term:
id: HP:0008707
label: Absent scrotum
evidence:
- reference: PMID:37932938
reference_title: "Calloso-adreno-scrotal agenesis associated with biallelic MAPK-activating death domain protein (MADD) variant: Further phenotypic delineation of MADD deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The novel findings include corpus callosum agenesis, bilateral adrenal agenesis, scrotal aplasia, and abnormal skin pigmentation"
explanation: Reports scrotal aplasia (absent scrotum) as a novel genital finding in MADD deficiency (single severe case).
biochemical:
- name: Blood Lactate
presence: Elevated
context: >-
Elevated blood lactate is reported in essentially all severe-form patients,
often with metabolic acidosis, reflecting systemic metabolic stress.
biomarker_term:
preferred_term: lactate
term:
id: CHEBI:24996
label: lactate
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "However, they all showed high lactate levels (Table 1)."
explanation: All patients in this cohort had elevated blood lactate.
experimental_models:
- name: MADD-deficient stem-cell-derived pancreatic islets
experimental_model_type: ORGANOID
description: >-
Human embryonic stem cell-derived pancreatic islets (self-organizing 3D
islet organoids) carrying the MADD exon 30-skipping splice variant, used to
model the endocrine (islet) dysfunction of MADD deficiency.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
publication: PMID:38775154
modeled_mechanisms:
- target: Endocrine and Exocrine Secretory Dysfunction
relationship: PARTIALLY_RECAPITULATES
fidelity: MODERATE
model_scale: CELLULAR
description: >-
Reduced beta-cell number, decreased insulin content, and an increased
proinsulin-to-insulin ratio in MADD-deficient islets model the pancreatic
endocrine component of the disease.
limitations: >-
An in-vitro stem-cell-derived islet model observes cellular/islet-level
readouts only; the organism-level combined endo-/exocrine and multisystem
dysfunction is inferred, and the model captures the pancreatic component
rather than the full endocrine spectrum (e.g. pituitary).
readouts:
- name: Beta-cell number, insulin content, proinsulin-to-insulin ratio
target: Endocrine and Exocrine Secretory Dysfunction
direction: DECREASED
interpretation: Reduced insulin content and beta-cell number report impaired islet endocrine output.
evidence:
- reference: PMID:38775154
reference_title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We observed reduced numbers of β cells, decreased insulin content, and increased proinsulin-to-insulin ratio in dex30 human embryonic stem cell-derived pancreatic islets."
explanation: Reports the islet measurements grounding this readout.
evidence:
- reference: PMID:38775154
reference_title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We discovered reduced differentiation efficiency of stem cell–derived dex30 pancreatic progenitors and deficient insulin content and processing in dex30 pancreatic β cells."
explanation: Supports treating the MADD-deficient islet model as informative for the endocrine dysfunction node.
treatments:
- name: Multidisciplinary Supportive Care
description: >-
No disease-modifying therapy exists. Management is supportive and
multidisciplinary, addressing the endocrine, exocrine, autonomic, and
hematologic organ systems - including nutritional support and management of
failure to thrive, glucose monitoring, and transfusion for anemia - with
genetic counseling for the family given autosomal recessive inheritance and
the potentially fatal early course of the severe form.
treatment_term:
preferred_term: Supportive Care
term:
id: NCIT:C15747
label: Supportive Care
evidence:
- reference: PMID:32761064
reference_title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The clinical course during the first years of life can be potentially fatal"
explanation: The severe, potentially fatal multisystem course frames management as supportive and multidisciplinary.
- name: Antiseizure Medication
description: >-
Seizures are treated with antiepileptic drugs and typically respond well;
reported agents include valproate, clonazepam, and phenytoin.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: valproate
term:
id: CHEBI:60654
label: valproate
- preferred_term: clonazepam
term:
id: CHEBI:3756
label: clonazepam
- preferred_term: phenytoin
term:
id: CHEBI:8107
label: phenytoin
evidence:
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "typically developed in the neonatal period and showed good response to antiepileptic drugs"
explanation: Reports that seizures respond well to antiepileptic drug therapy.
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "generalized tonic-clonic seizures at the age of one month that showed good response to valproate"
explanation: Substantiates valproate as a reported antiseizure agent with good response.
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Generalized seizures began at 9 months of life that showed reasonable control on a combination of valproate and clonazepam"
explanation: Substantiates valproate plus clonazepam as reported antiseizure agents.
- reference: PMID:38459224
reference_title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Her seizures were reasonably controlled with phenytoin"
explanation: Substantiates phenytoin as a reported antiseizure agent.
references:
- reference: PMID:32761064
title: "Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder."
- reference: PMID:40812422
title: "Neurodevelopmental disorder mutations in the exchange factor DENN/MADD disrupt activation of Rab GTPases."
- reference: PMID:38459224
title: "New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder."
- reference: PMID:37932938
title: "Calloso-adreno-scrotal agenesis associated with biallelic MAPK-activating death domain protein (MADD) variant: Further phenotypic delineation of MADD deficiency."
- reference: PMID:38775154
title: "A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes."
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Address automated review on PR #11128 (DEEAH/MADD) · 2026-09-05T16:52:56Z · View source
Bundled response to the automated CHANGES_REQUESTED review on PR #11128. CRITICAL: re-cited Cryptorchidism to PMID:38459224 (70% of males, undescended testis) and added a separate Scrotal aplasia phenotype (HP:0008707) carrying the original PMID:37932938 finding. IMPORTANT: added reference_title to all evidence items and a top-level references block; re-cited Antiseizure treatment to PMID:38459224 (good AED response) with valproate/clonazepam/phenytoin therapeutic_agents; added high-frequency phenotypes Hypopituitarism (HP:0040075), Secondary growth hormone deficiency (HP:0008240) from PMID:38775154, Recurrent apnea (HP:0002104) and Congenital heart disease (HP:0001627) from PMID:38459224, each linked from the appropriate pathophysiology node; fixed frequency grades (Thrombocytopenia OCCASIONAL->FREQUENT; dropped frequency on the single-case Agenesis of corpus callosum); relabeled the apoptosis node/edge to reflect the fibroblast assay (causal_link_type INDIRECT_KNOWN/UNKNOWN_INTERMEDIATES, directness INDIRECT, fibroblast cell type); regraded two Brain-2020 fibroblast-conclusion snippets HUMAN_CLINICAL->IN_VITRO; dropped the wrong therapeutic_modality BEHAVIORAL from Supportive Care. SUGGESTIONS taken: genotype-severity P372L/L346P evidence (PMID:40812422); MADD-deficient hESC islet experimental_models join to the endocrine node (PMID:38775154); external_assertions for OMIM:619004/Orphanet:686495/MedGen and a Blood Lactate biochemical block; explicit spectrum-scope statement in the description (single entry, not has_subtypes). Not done: clinical hypothyroidism, exocrine pancreatic insufficiency, pain insensitivity, and hypohidrosis phenotypes were omitted because their fractions live only in the abstract-only Schneeberger Table 1 / DR report and no exact primary-source snippet was available. Validated: just validate (39/39 snippets), validate-disorders, validate-terms, all check-* gates, validate-history.
Create: Deeah Syndrome (MADD) · 2026-09-05T16:06:11Z · View source
Created DEEAH syndrome (developmental delay with endocrine, exocrine, autonomic, and hematologic abnormalities; MONDO:0033561), an autosomal recessive multisystem disorder from biallelic loss-of-function MADD (the gene MAP-kinase-activating death domain, hgnc:6766 - NOT the acyl-CoA metabolic disorder abbreviation MADD). Curated entry_type DISEASE. Pathograph: biallelic MADD LoF -> impaired DENN/Rab-GEF vesicular trafficking (Rab3/Rab27, EGF endocytosis defect) and impaired TNF-alpha/ERK1-2 cytoprotective signaling -> increased neuronal apoptosis (caspase-3/-7) plus endocrine/exocrine secretory and autonomic/sensory dysfunction. Evidence from Schneeberger et al 2020 Brain (PMID:32761064, defining cohort, patient-fibroblast functional studies), Khan et al 2025 JBC (PMID:40812422, DENN/MADD Rab-GEF substrate mapping), Abou-Nader/Elbendary 2024 J Hum Genet (PMID:38459224, spectrum + frequencies), and Darouich 2024 AJMG (PMID:37932938, calloso-adreno-scrotal case). Deep research: claude_code literature sweep (research/Deeah_Syndrome-deep-research-claude_code.md); its single PMID (11359932, mouse Rab3-GEP) was flagged off-topic and not cited. Watched for MADD gene vs acyl-CoA disease confusion throughout. Validated: just validate, just validate-terms, just validate-disorders (29/29 snippets verified), all path-accepting check-* gates.
"MADD" is a dangerous acronym collision. The gene symbol MADD (MAP-kinase Activating Death Domain protein, chr 11p11.2, HGNC:6766, OMIM 603584) is unrelated to "MADD" = Multiple Acyl-CoA Dehydrogenase Deficiency (glutaric acidemia type II; caused by ETFA/ETFB/ETFDH*), a distinct fatty-acid-oxidation disorder with its own newborn-screening profile and riboflavin-responsive treatment (GeneReviews: NBK558236). Any literature search on "MADD" pulls both entities; curators must filter by gene identity (MADD/Rab3-GEF DENN-domain protein) vs. metabolic disease acronym. This is a textbook Named Entity Confusion risk for the KB.
Deeah syndrome ("Developmental delay, Endocrine dysfunction, Exocrine dysfunction, Autonomic dysfunction, Hematologic abnormalities") is the severe end of a phenotypic spectrum caused by biallelic pathogenic variants in MADD. It was delineated as a distinct entity by Schneeberger et al. (Brain, 2020; PMID: 32761064; PMC7447524), who described 14 patients from 11 families with a severe multisystemic perinatal-onset disorder, versus a second group of 9 patients with a milder, predominantly neurological phenotype.
Key identifiers: - OMIM: #619004 (DEEAH syndrome); allelic disorder #619005 NEDDISH (Neurodevelopmental disorder with Dysmorphic facies, Impaired Speech, and Hypotonia — the milder end of the spectrum) - Gene (causal): MADD, OMIM 603584, HGNC:6766, chr 11p11.2, Ensembl ENSG00000110514, UniProt Q8WXG6 - MONDO: MONDO:0033561 - Orphanet: ORPHA:686495 - MedGen: C5436579 - UniProt disease entry:* DI-05908 - No dedicated ICD-10/ICD-11 code exists; it would fall under an unspecified developmental/genetic syndrome code in practice.
Synonyms: MADD-related developmental delay–endocrine dysfunction–hypohemoglobinemia syndrome; MADD deficiency (severe form); developmental delay with endocrine, exocrine, autonomic, and hematologic abnormalities.
Evidence basis: aggregated case series from multiple independent centers (Schneeberger et al. 2020, n=14+9; a 2024 expansion cohort, n=5 additional; sporadic case reports) rather than a single large disease-level registry — this is a genotype-first, multicenter case-collection literature, not EHR-derived.
Disease causal factor: Biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic variants in MADD. This is a purely monogenic, autosomal recessive disorder — no environmental or infectious contribution has been reported.
Genetic risk factors: - Parental consanguinity is common; the 2024 expansion cohort reported 100% consanguinity in their 5 families versus 33% in prior literature (PMC11126384, PMID: 38459224). - 21+ distinct pathogenic variants reported across the literature as of the 2020–2024 series: 9 missense (5 clustered in the central DENN catalytic domain), 5 nonsense, 3 splice-site, 3 frameshift, and 1 multi-exon (11–24) deletion. - No population-specific founder variant has been established; variants are largely private to individual families, consistent with an ultra-rare disorder without an ethnic-specific hotspot reported to date.
Protective factors: None reported — no protective alleles, modifier loci, or environmental protective exposures are described in the literature.
Gene-environment interaction: None described. The 2024 paper explicitly notes the absence of genotype-phenotype correlation (missense and truncating variants both associate with severe disease) and speculates that "environmental/epigenetic modifiers may influence severity," but this is unconfirmed hypothesis, not established interaction.
The phenotype spectrum bifurcates into two clinically distinguishable groups (Schneeberger et al. 2020), which map onto the two OMIM entries:
| Phenotype | Frequency | Suggested HPO term |
|---|---|---|
| Severe developmental delay / hypotonia | 14/14 | HP:0001263 (Global developmental delay); HP:0001252 (Hypotonia) |
| Recurrent apnea/desaturation, neonatal onset | 13/14 | HP:0002104 (Apnea) |
| Exocrine pancreatic insufficiency | 13/14 | HP:0001738 (Exocrine pancreatic insufficiency) |
| Constipation/diarrhea | 13/14 | HP:0002019 / HP:0002014 |
| Anemia | 13/14 | HP:0001903 |
| Hypopituitarism | 8/12 | HP:0040075 |
| Growth hormone deficiency | 8/10 | HP:0000824 |
| Reduced pain sensation | 9/12 | HP:0007021 |
| Fever dysregulation | 11/13 | HP:0025144 (Recurrent fever) / thermodysregulation |
| Hypothyroidism | 6/13 | HP:0000821 |
| Reduced sweating | 6/11 | HP:0000966 (Anhidrosis) |
| Thrombocytopenia | 5/14 | HP:0001873 |
| Early lethality | 7/14 (6 before age 3; 1 at 7.5y) | HP:0034241 (Reduced life expectancy) |
Onset: Congenital/perinatal for Group 1 (presenting with respiratory failure and apnea in the neonatal period); infantile/early childhood for Group 2. Progression: Group 1 is a multi-organ, often fatal disorder with high early mortality; Group 2 is a stable-to-slowly-progressive neurodevelopmental disorder with better survival. Quality of life impact: Severe in both groups given intellectual disability and, in Group 1, high mortality and dependence on multidisciplinary supportive care (feeding support, hormone replacement, respiratory monitoring). No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare disorder.
Causal gene: MADD (MAP-Kinase Activating Death Domain protein, also historically called Rab3 GDP/GTP exchange protein / Rab3GEP / DENN/MADD), HGNC:6766, OMIM *603584, 11p11.2.
Variant spectrum (from Schneeberger 2020 + 2024 expansion, ~28 variants total reported to date): - Missense (largest class, 9+): 5 cluster within the central catalytic DENN domain. Representative: c.914G>T p.(Gly305Val); c.3119T>G p.(Leu1040Arg); the earlier NEDDISH founder-like report of p.Arg198His. - Nonsense: recurrent c.979C>T p.(Arg327Ter); c.2620C>T p.(Arg874Ter); the classic NEDDISH allele p.Arg327Ter. - Splice-site: c.963+1G>A (homozygous); a distinct splice variant reported to selectively impair pancreatic β-cell and pituitary gonadotrope isoforms (JCI Insight, PMID: 38775154). - Frameshift: c.4321delC p.(Gln1441ArgfsTer46). - Structural: one multi-exon deletion spanning exons 11–24.
Variant classification: Nearly all reported alleles are classified pathogenic/likely pathogenic per ACMG/AMP criteria in ClinVar; at least one VUS reported in the 2024 cohort (c.4307G>A p.(Arg1436Gln)).
Population frequency: MADD biallelic loss-of-function is not represented at appreciable frequency in gnomAD population data given the severity of the phenotype (consistent with strong purifying selection against complete loss of function; specific LOEUF/pLI values were not independently confirmed in this research pass and should be pulled directly from the gnomAD browser before curation).
Functional consequence — mechanistically established: - Truncating variants (nonsense, frameshift) reduce mRNA to 40–48% of control via nonsense-mediated decay, and protein to near-absent levels (0–4% of control) in patient fibroblasts (PMC7447524). - Missense variants act via structural disruption of Rab-GTPase engagement rather than simple loss of protein (see Mechanism, below). - No dominant-negative or gain-of-function alleles have been reported; the mechanism is consistently loss-of-function/hypomorphic.
Modifier genes: None established.
Epigenetic information: Not reported for this disorder specifically.
Chromosomal abnormalities: Not applicable — this is a sequence-variant, not a copy-number/aneuploidy, disorder (aside from the one reported multi-exon deletion, which is a private intragenic structural variant, not a recurrent CNV).
No environmental, lifestyle, or infectious contributing factors have been reported for MADD-related disorder — it is a fully penetrant monogenic condition. This section is not applicable beyond noting the absence of such findings in the literature to date.
Molecular pathways: Rab GTPase vesicle trafficking pathway (Reactome/KEGG "vesicle-mediated transport"); TNFR1–MAPK/ERK signaling; apoptosis (caspase-3/7) pathway.
Cellular processes: Regulated exocytosis (synaptic vesicle release, zymogen granule secretion, hormone granule secretion), receptor-mediated endocytosis, apoptosis.
Suggested GO terms: GO:0032482 (Rab protein signal transduction), GO:0017112 (Rab guanyl-nucleotide exchange factor activity), GO:0006887 (exocytosis), GO:0007249 (I-kappaB kinase/NF-kappaB signaling — via TNFR1 adaptor role), GO:0043065 (positive regulation of apoptotic process), GO:0006886 (intracellular protein transport).
Suggested CL terms: CL:0000169 (pancreatic type B cell / β-cell), CL:0002064 (pancreatic acinar cell), CL:0000473 (pituitary gonadotrope cell), CL:0000540 (neuron).
Molecular profiling: No transcriptomic/proteomic/single-cell datasets specific to patient tissue were identified in this pass beyond the hESC-derived islet model (PMID: 38775154) and patient fibroblast functional assays (PMID: 32761064). No GEO/ArrayExpress series specific to this disorder was located; this should be verified directly against GEO before asserting absence.
Organ level: Central and peripheral nervous system (primary, both groups); endocrine pancreas, exocrine pancreas, pituitary gland, thyroid, gonads (Group 1); bone marrow/hematopoietic system (anemia, thrombocytopenia); heart (congenital heart disease, reported in later cohorts); autonomic nervous system (sweat glands, thermoregulatory centers).
Tissue/cell level: Neurons (synaptic terminals — Rab3-dependent vesicle release); pancreatic acinar cells (exocrine secretion); pancreatic β-cells (insulin granule secretion); pituitary gonadotropes (LH/FSH granule secretion).
Subcellular level: Synaptic vesicles, secretory/zymogen granules, endosomes (receptor internalization), mitochondria (Rab recruitment assays in PMID: 40812422 used mitochondrial relocalization as a GEF-activity readout).
Suggested UBERON terms: UBERON:0001264 (pancreas), UBERON:0000955 (brain), UBERON:0013422 (developing anatomical structure — perinatal context), UBERON:0000007 (pituitary gland). Suggested GO Cellular Component: GO:0008021 (synaptic vesicle), GO:0042589 (zymogen granule membrane).
Localization: Diffuse/systemic (multi-organ) in Group 1; primarily CNS in Group 2. No lateralization pattern reported.
Epidemiology: Ultra-rare. Approximately 23 patients (17 families) in the founding 2020 series plus ~5 additional patients (2024 expansion) and scattered case reports — total reported patients likely in the low 30s as of this research pass. No formal population prevalence or incidence estimate exists; Orphanet lists it as an ultra-rare disorder (ORPHA:686495) without a numeric prevalence class. This figure should be re-verified against the current Orphanet record before use in a KB prevalence: block, since exact current counts were not independently confirmed against the live Orphanet page in this pass (Orphanet fetch was not attempted directly).
Population demographics: No specific ethnic enrichment beyond the consanguinity signal; no sex ratio skew reported (autosomal recessive, no differential sex susceptibility described beyond male-specific genital findings — undescended testis/micropenis — which are simply male-specific phenotype expressions, not a prevalence skew).
There is no disease-modifying or targeted therapy; management is entirely supportive and multidisciplinary, addressing each organ-system manifestation:
No gene therapy, RNA-based therapy, or targeted molecular therapy has been reported or is in registered clinical trials for this disorder as of this research pass (a ClinicalTrials.gov/WHO ICTRP search specific to MADD-related disorder should be run directly before asserting a negative in a KB entry, since this pass relied on literature search rather than a direct trial-registry query).
No primary prevention exists beyond genetic counseling and carrier/prenatal testing in families with a known pathogenic MADD allele, particularly relevant given the strong consanguinity association. No screening program, immunization strategy, or public-health intervention applies to this monogenic disorder. Secondary/tertiary prevention consists of early recognition of the neonatal respiratory/hypotonic presentation to enable prompt supportive care and multidisciplinary surveillance for the emerging endocrine/exocrine complications.
No naturally occurring veterinary disease counterpart was identified in this research pass (no OMIA entry located). The Madd mouse ortholog (MGI:2444672) is used exclusively as an engineered knockout model (see below), not a naturally occurring disease model.
Mouse — Madd/Rab3GEP knockout (MGI:2444672):
- Tanaka et al., Mol Biol Cell 2001, PMID: 11359932 — Rab3GEP−/− mice develop normally in utero but die immediately after birth; at E18.5, no evoked action potentials were recordable at the diaphragm/gastrocnemius neuromuscular junction upon phrenic/sciatic nerve stimulation, and hippocampal neurons showed markedly reduced vesicular release probability without a change in readily-releasable-pool size.
- Fidelity assessment: This is a complete-null, whole-organism model that recapitulates the neuromuscular/synaptic-transmission defect underlying the severe Group 1/DEEAH phenotype (respiratory failure at birth mirrors the human perinatal apnea/respiratory-insufficiency presentation) but is a constitutive null, so it cannot model the milder, hypomorphic NEDDISH phenotype or long-term survival features (endocrine, hematologic) since the mice do not survive past birth. This is a FAILS_TO_RECAPITULATE-flavored limitation for chronic/postnatal features, alongside RECAPITULATES for the acute perinatal neuromuscular phenotype.
- Human iPSC/hESC-derived pancreatic islet model (MADD-deficient) — PMID: 38775154 — an in vitro human cellular model (not an animal model) recapitulating reduced β-cell number, decreased insulin content, and increased proinsulin:insulin ratio, directly modeling the endocrine-pancreas arm of the human phenotype; high fidelity for the β-cell secretory defect specifically, though it does not model the whole-organism multisystem phenotype.
No zebrafish, Drosophila, or C. elegans MADD-ortholog disease model was identified in this pass (note C. elegans rab-3/rab-27 synaptic transmission literature exists — PMC1474797 — but as basic Rab biology, not as a modeled MADD-disease-variant knock-in).
| PMID | Citation | Contribution |
|---|---|---|
| 32761064 | Schneeberger et al., Brain 2020;143(8):2437-2453 | Founding clinical/functional description; 23 patients, 17 families; defines DEEAH/NEDDISH spectrum; TNF-α/ERK/caspase and vesicular-trafficking functional data |
| 38459224 | J Hum Genet 2024 (Journal of Human Genetics) | 5-patient expansion cohort; arthrogryposis, elevated lactate, congenital heart disease, brain MRI findings; consanguinity enrichment |
| 38775154 | JCI Insight 2024 | Splice-site variant; hESC-derived islet and gonadotrope model; mechanistic basis for diabetes and hypogonadotropic hypogonadism |
| 40812422 | J Biol Chem 2025 (Khan, Kumar, Trempe, Francis, et al.) | Structural/biochemical basis for genotype-phenotype divergence via differential Rab-GTPase substrate engagement (P372L vs. L346P) |
| 11359932 | Tanaka et al., Mol Biol Cell 2001 | Madd/Rab3GEP knockout mouse — perinatal lethal neuromuscular transmission defect |
| 9115275 | Original MADD gene/TNFR1 death-domain characterization | Establishes MADD as a TNFR1 adaptor linking to MAPK/apoptotic signaling |
Caveat on this report: Several quantitative claims (patient totals, mortality percentages, specific variant lists) were extracted via automated summarization of PMC full-text pages rather than my own direct reading of primary-source PDF text; before committing any specific number, percentage, or exact quote to a dismech evidence: snippet, the cited PMID should be independently re-verified against the actual abstract/full-text per the dismech-references skill's exact-quote requirement. The OMIM clinical synopsis (omim.org) could not be fetched directly (403 Forbidden) in this session, so DEEAH/NEDDISH clinical-synopsis category assignments here derive from secondary web summaries of that page and should be cross-checked against the primary OMIM entry if institutional access is available.
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 9 |
| Resolved | 9 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 9 |
| On topic | 6 |
| Off topic | 1 |
These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:
PMID:11359932 (3 mentions) - Role of Rab3 GDP/GTP exchange protein in synaptic vesicle trafficking at the mouse neuromuscular junction.Weighed against this report's own most characteristic terms: disorder, madd, cohort, neddish, phenotype, exocrine, disease, variant, endocrine, deeah, severe, patient, genetic, pancreatic, gene, directly, respiratory, delay, developmental, apnea.
All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.
Checked with linkml-term-validator 0.4.5, through the ols: adapter.
| Outcome | Count |
|---|---|
| Terms checked | 59 |
| Resolved | 53 |
| Unresolved (possible confabulation) | 1 |
| Obsolete | 2 |
| Unverifiable | 3 |
| Terms whose name was checked | 30 |
| Terms named correctly | 19 |
| Terms named as a different term | 7 |
| Terms whose name is worth a second look | 4 |
These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:
HP:0025144 (1 mention) - the report calls it "Recurrent fever"; HP calls it ShiveringHP:0034241 (1 mention) - the report calls it "Reduced life expectancy"; HP calls it Prenatal deathGO:0017112 (1 mention) - the report calls it "Rab guanyl-nucleotide exchange factor activity"; GO calls it GO_0017112CL:0000473 (1 mention) - the report calls it "pituitary gonadotrope cell"; CL calls it OBSOLETE defensive cellUBERON:0013422 (1 mention) - the report calls it "developing anatomical structure — perinatal context"; UBERON calls it infratemporal fossaNCIT:C50384 (1 mention) - the report calls it "Respiratory Support"; NCIT calls it TOP2B wt AlleleNCIT:C560 (1 mention) - the report calls it "Pancrelipase"; NCIT calls it HydroxyureaThese identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:
HP:0005088 (1 mention) - HP does not contain this termThese terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:
GO:0017112 (GO_0017112) (1 mention) - replaced by GO:0005085CL:0000473 (OBSOLETE defensive cell) (1 mention)The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:
HP:0000966 (1 mention) - the report calls it "Anhidrosis"; HP calls it HypohidrosisGO:0007249 (1 mention) - the report calls it "I-kappaB kinase/NF-kappaB signaling — via TNFR1 adaptor role"; GO calls it canonical NF-kappaB signal transduction, and lists "I-kappaB kinase/NF-kappaB signaling" among its other namesCL:0000169 (1 mention) - the report calls it "pancreatic type B cell / β-cell"; CL calls it type B pancreatic cellNCIT:C159273 (1 mention) - the report calls it "Speech Therapy"; NCIT calls it Speech Language TherapyTerms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.